A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.

MLA

Denlinger, Crystal S., et al. “A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients with Advanced Biliary Tract Cancers.” Clinical Colorectal Cancer, vol. 13, no. 2, June 2014, pp. 81–86. EBSCOhost, https://doi.org/10.1016/j.clcc.2013.12.005.

APA

Denlinger, C. S., Meropol, N. J., Li, T., Lewis, N. L., Engstrom, P. F., Weiner, L. M., Cheng, J. D., Alpaugh, R. K., Cooper, H., Wright, J. J., & Cohen, S. J. (2014). A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers. Clinical Colorectal Cancer, 13(2), 81–86. https://doi.org/10.1016/j.clcc.2013.12.005

Chicago

Denlinger, Crystal S, Neal J Meropol, Tianyu Li, Nancy L Lewis, Paul F Engstrom, Louis M Weiner, Jonathan D Cheng, et al. 2014. “A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients with Advanced Biliary Tract Cancers.” Clinical Colorectal Cancer 13 (2): 81–86. doi:10.1016/j.clcc.2013.12.005.